FDA
-
-
-
-
-
-
-
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
-
-
-
-
-
-
-
AB Science reports initial results from cancer drug trial
-
-
-
-
-
-
-
AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease
-
-
-
-
-
-
-
AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement
-
-
-
-
-
-
-
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter
-
-
-
-
-
-
-
Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland
-
-
-
-
-
-
-
AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)
-
325,890 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All
